Deutsche Bank AG Takes $156.34 Million Position in Waters Corporation $WAT

Key Points

• Deutsche Bank acquired 416,850 Waters shares worth approximately $156.3 million, representing a 0.42% stake; institutional investors collectively own 94.01% of the company.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $420.35, supported by several recent target increases and “Buy” or “Outperform” ratings.
• Waters exceeded quarterly expectations with adjusted EPS of $3.05 versus $3.01 expected and revenue of $1.65 billion; shares opened at $416.45, near the company’s 52-week high of $420.26.

Deutsche Bank AG acquired a new stake in Waters Corporation (NYSE:WAT - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 416,850 shares of the medical instruments supplier's stock, valued at approximately $156,335,000. Deutsche Bank AG owned 0.42% of Waters as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Pinnacle Associates Ltd. grew its position in Waters by 0.3% during the fourth quarter. Pinnacle Associates Ltd. now owns 7,608 shares of the medical instruments supplier's stock worth $2,890,000 after buying an additional 26 shares during the period. Exencial Wealth Advisors LLC lifted its position in shares of Waters by 1.7% during the 4th quarter. Exencial Wealth Advisors LLC now owns 1,681 shares of the medical instruments supplier's stock valued at $638,000 after acquiring an additional 28 shares during the period. Clearstead Advisors LLC lifted its position in shares of Waters by 5.1% during the 4th quarter. Clearstead Advisors LLC now owns 616 shares of the medical instruments supplier's stock valued at $234,000 after acquiring an additional 30 shares during the period. Avalon Trust Co boosted its stake in shares of Waters by 2.3% during the 1st quarter. Avalon Trust Co now owns 1,330 shares of the medical instruments supplier's stock worth $396,000 after acquiring an additional 30 shares in the last quarter. Finally, Integrated Wealth Concepts LLC boosted its stake in shares of Waters by 2.9% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier's stock worth $386,000 after acquiring an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company's stock.

Insider Activity

In related news, Director Christopher A. Kuebler sold 3,626 shares of the firm's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the sale, the director owned 17,808 shares in the company, valued at approximately $7,086,515.52. This trade represents a 16.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.31% of the company's stock.

Wall Street Analysts Forecast Growth

WAT has been the subject of several research analyst reports. Wolfe Research initiated coverage on Waters in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $425.00 price objective for the company. Royal Bank Of Canada lifted their price objective on Waters from $435.00 to $475.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Barclays boosted their target price on Waters from $425.00 to $460.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 5th. The Goldman Sachs Group upped their target price on Waters from $380.00 to $425.00 and gave the company a "buy" rating in a report on Tuesday, July 14th. Finally, Wells Fargo & Company raised their price target on Waters from $370.00 to $400.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Waters currently has an average rating of "Moderate Buy" and an average price target of $420.35.

Waters Trading Up 3.8%

Shares of WAT stock opened at $416.45 on Thursday. The company has a market capitalization of $40.92 billion, a price-to-earnings ratio of 103.85, a PEG ratio of 2.33 and a beta of 1.19. The company has a current ratio of 1.86, a quick ratio of 1.29 and a debt-to-equity ratio of 0.32. The firm has a 50-day moving average price of $379.73 and a 200 day moving average price of $346.54. Waters Corporation has a twelve month low of $282.77 and a twelve month high of $420.26.

Waters (NYSE:WAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.01 by $0.04. The company had revenue of $1.65 billion for the quarter, compared to analysts' expectations of $1.62 billion. Waters had a net margin of 3.58% and a return on equity of 11.27%. The firm's revenue for the quarter was up 113.3% compared to the same quarter last year. During the same period last year, the company earned $2.95 EPS. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Research analysts forecast that Waters Corporation will post 14.57 earnings per share for the current fiscal year.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Corporation (NYSE:WAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source